Advocacy intelligence hub — real-time data for patient organizations
Neulasta: FDA approved
To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome)
Neupogen: FDA approved
To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome).
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Neulasta
Amgen, Inc.
Patient Assistance Programs1
Neupogen
Amgen, Inc.
Neulasta
(Pegfilgrastim)Orphan drugAmgen, Inc.
Leukocyte Growth Factor [EPC]
12.1 Mechanism of Action Pegfilgrastim products are colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface rec...
Browse all Difference of sex development of gynecological interest news →
View all Difference of sex development of gynecological interest specialists →